T-KNIFE
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRฮฑฮฒ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
T-KNIFE
Social Links:
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.t-knife.com
Total Employee:
51+
Status:
Active
Total Funding:
197.44 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Google Tag Manager Google Analytics Content Delivery Network Amazon Global Site Tag Google Analytics 4 Amazon Virginia Region
Similar Organizations
Achilles Therapeutics
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Lava Therapeutics
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Casdin Capital
Casdin Capital investment in Series B - T-knife
Versant Ventures
Versant Ventures investment in Series B - T-knife
Qatar Investment Authority
Qatar Investment Authority investment in Series B - T-knife
Andera Partners
Andera Partners investment in Series B - T-knife
RA Capital Management
RA Capital Management investment in Series B - T-knife
Fidelity
Fidelity investment in Series B - T-knife
CaaS Capital Management
CaaS Capital Management investment in Series B - T-knife
EQT Life Sciences
EQT Life Sciences investment in Series B - T-knife
Sixty Degree Capital
Sixty Degree Capital investment in Series B - T-knife
Andera Partners
Andera Partners investment in Series A - T-knife
Key Employee Changes
| Date | New article |
|---|---|
| 2023-11-06 | T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer |
Official Site Inspections
http://www.t-knife.com Semrush global rank: 4.79 M Semrush visits lastest month: 1.86 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "T-knife"
Management & Board of Directors | T-knife Therapeutics
About T-knife. T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) โฆSee details»
T-knife - Crunchbase Company Profile & Funding
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRฮฑฮฒ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient โฆSee details»
Pipeline | TK-8001 | TK-2504 | Clinical Trials - T-knife
Why T-knife; Mission and Values; Job Opportunities; Contact; Pipeline. We are advancing a proprietary portfolio of TCR-T product candidates, for which we retain worldwide commercial rights. PRAME is found in cancers of the skin, โฆSee details»
T-knife - Org Chart, Teams, Culture & Jobs | The Org
View T-knife's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
T-Knife GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Explore T-Knife GmbH with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 9 news, and 2 literature, Disease Domain:Neoplasms, Technology Platform:TCR โฆSee details»
T-knife (T-Knife GmbH) - startbase.com
News about T-knife. Comprehensive Startup Listings: Startups from Berlin Startups from Berlin Startups from Germany. Recent mentions of T-knife in podcasts & videos: Jobs at T-knife: โฆSee details»
T-knife - Contacts, Employees, Board Members, Advisors & Alumni
T-knife has 6 board members and advisors, including Thomas Blankenstein. Thomas Blankenstein Board Member Aug 6, 2020 Alexander Mayweg Board Member Aug 6, 2020See details»
T-Knife - EQT Group
Dec 2, 2024 T-knife is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) Sector HealthcareSee details»
T-knife Company Profile - Office Locations, Competitors ... - Craft
T-knife has 5 employees at their 1 location and $110 m in total funding,. See insights on T-knife including office locations, competitors, revenue, financials, executives, subsidiaries and more โฆSee details»
T-Knife Therapeutics Company Profile 2024: Valuation, โฆ
Mar 14, 2018 T-Knife Therapeutics General Information Description. Developer of T cell receptor therapies designed to treat cancer. The company's therapies use a humanized TCR mice platform to carry human gene loci and recombine โฆSee details»
T-knife - Funding, Financials, Valuation & Investors - Crunchbase
T-knife is a developer of T cell receptors intended for T cell therapy of cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»
T-knife - Overview, News & Similar companies | ZoomInfo.com
Feb 8, 2023 T-knife contact info: Phone number: +49 3094892432 Website: www.t-knife.com What does T-knife do? Founded in 2018 and headquartered in Berlin, Germany, T-knife is a โฆSee details»
T-KNIFE - VentureRadar
T-knifeโs discovery engine has fueled a pipeline of TCR-T product candidates against solid tumor targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and โฆSee details»
Berlin start-up T-knife raises $110 million | Max Delbrück Center
Aug 2, 2021 T-knifeโs lead program, TK-8001, is a novel TCR-T product candidate. It targets solid tumors that carry the antigen MAGE-A1 โ a typical distinguishing feature on the surface โฆSee details»
Press Release - T-knife
Jan 19, 2021 T-knife is backed by leading investors, including Versant Ventures, RA Capital, Andera Partners, and Boehringer Ingelheim Venture Fund. Contact. T-knife GmbH Camille โฆSee details»
T-knife Therapeutics Announces $110 Million Series B
Aug 2, 2021 T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product โฆSee details»
T-knife Therapeutics Announces $110 Million Series B Financing to ...
Aug 2, 2021 T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product โฆSee details»
T-knife Therapeutics bags $110M to sharpen solid tumor cell โฆ
Aug 2, 2021 T-knife will use the money to start enrolling patients with MAGE-A1 positive cancers in a phase 1/2 trial in the fourth quarter. Next year, T-knife plans to submit applications to run โฆSee details»
Knife Maintenance 101: How to Care for Your Condor Knife to Last โฆ
Nov 28, 2024 A typical knife consists of the blade, handle, tang, edge, and sometimes additional components like the guard or pommel. Each part requires proper care and โฆSee details»
Knife River to acquire Strata for $454M - Nasdaq
1 day ago Knife River (KNF) announced that it has entered into a definitive agreement to acquire Strata. Based on Strataโs projected 2025 adjusted EBITDA, the purchase price of $454M โฆSee details»